CO5261608A1 - Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina - Google Patents
Composicion farmaceutica en forma de una suspension que comprende oxcarbazepinaInfo
- Publication number
- CO5261608A1 CO5261608A1 CO00094330A CO00094330A CO5261608A1 CO 5261608 A1 CO5261608 A1 CO 5261608A1 CO 00094330 A CO00094330 A CO 00094330A CO 00094330 A CO00094330 A CO 00094330A CO 5261608 A1 CO5261608 A1 CO 5261608A1
- Authority
- CO
- Colombia
- Prior art keywords
- suspension
- oxcarbazepine
- composition according
- milliliter
- grams
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Hydrogenated Pyridines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s. Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y una mezcla de carboximetilcelulosa y celulosa microcristalina, en una escala del 1.25 al 1.95 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con la reivindicación 2, en donde la proporción de la carboximetilcelulosa a la celulosa microcristalina en la mezcla es de 1: 5 a 1:12. Una composición de acuerdo con la reivindicación 2 ó 3, en donde la carboximetilcelulosa en la mezcla es una sal sódica. Una composición de acuerdo con cualquiera de las reivindicaciones 1 a 4, la cual comprende un antioxidante. Una composición de acuerdo con la reivindicación 5, en donde el antioxidante es ácido ascórbico. Una composición de acuerdo con la reivindicación 5 ó 6, en donde el antioxidante está presente en una escala del 0.75 al 2 por ciento (gramos/mililitro)de la composición total. Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, que tiene un pH en la escala de 2 a 4.Una composición de acuerdo con cualquiera de las reivindicaciones anteriores, la cual comprende oxcarbazepina en una cantidad del 1 al 20 por ciento (gramos/mililitro). Una composición farmacéutica en la forma de una suspensión que comprende oxcarbazepina y menos del 0.5 por ciento (gramos/mililitro)de hidroxietilcelulosa. Un recipiente que tiene un volumen de llenado de aproximadamente 50 mililitros a aproximadamente 300 mililitros, el cual comprende una suspensión de oxcarbazepina de acuerdo con cualquiera de las reivindicaciones anteriores, y una jeringa dosificadora adaptada para ajustarse a este recipiente. Una composición farmacéutica en la forma de una suspensión tixotrópica oral que comprende el 6 por ciento (gramos/mililitro)de oxcarbazepina, y que tiene, cuando se agita, una viscosidad en la escala de 5 a 52 mPa. s.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9930058.4A GB9930058D0 (en) | 1999-12-20 | 1999-12-20 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5261608A1 true CO5261608A1 (es) | 2003-03-31 |
Family
ID=10866648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00094330A CO5261608A1 (es) | 1999-12-20 | 2000-12-12 | Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina |
Country Status (34)
Country | Link |
---|---|
US (1) | US8119148B2 (es) |
EP (2) | EP1437127A1 (es) |
JP (2) | JP4588281B2 (es) |
KR (2) | KR20040098034A (es) |
CN (1) | CN1216594C (es) |
AR (1) | AR030175A1 (es) |
AT (1) | ATE269694T1 (es) |
AU (1) | AU777619B2 (es) |
BE (2) | BE1013706A5 (es) |
BR (1) | BR0016524A (es) |
CA (1) | CA2390029C (es) |
CO (1) | CO5261608A1 (es) |
CZ (1) | CZ302737B6 (es) |
DE (1) | DE60011809T2 (es) |
DK (1) | DK1239832T3 (es) |
ES (1) | ES2223641T3 (es) |
FR (1) | FR2802423B1 (es) |
GB (1) | GB9930058D0 (es) |
HK (1) | HK1050474A1 (es) |
HU (1) | HU226486B1 (es) |
IL (2) | IL149498A0 (es) |
IT (1) | ITMI20002717A1 (es) |
MX (1) | MXPA02006142A (es) |
MY (1) | MY126868A (es) |
NO (1) | NO331990B1 (es) |
NZ (1) | NZ518755A (es) |
PE (1) | PE20010933A1 (es) |
PL (1) | PL201331B1 (es) |
PT (1) | PT1239832E (es) |
RU (1) | RU2277912C2 (es) |
SK (1) | SK287553B6 (es) |
TR (2) | TR200201459T2 (es) |
WO (1) | WO2001045671A2 (es) |
ZA (1) | ZA200204863B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
DE10224086A1 (de) * | 2002-05-31 | 2003-12-11 | Bayer Ag | Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker |
GB0221956D0 (en) * | 2002-09-20 | 2002-10-30 | Novartis Ag | Organic compounds |
EP1539098B1 (en) | 2002-09-20 | 2011-08-10 | Fmc Corporation | Cosmetic composition containing microcrystalline cellulose |
RU2369393C2 (ru) | 2003-09-03 | 2009-10-10 | Новартис Аг | Применение окскарбазепина для лечения диабетической нейропатической боли и для улучшения сна |
US20060252745A1 (en) | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
WO2007007182A2 (en) * | 2005-07-08 | 2007-01-18 | Aurobindo Pharma Limited | Solid and liquid dosage forms of an antiepileptic agent |
US9198862B2 (en) | 2005-07-22 | 2015-12-01 | Rubicon Research Private Limited | Dispersible tablet composition |
EP2359830B1 (en) * | 2006-04-26 | 2012-09-19 | Supernus Pharmaceuticals, Inc. | Controlled released preparations of oxcarbazepine having sigmoidal release profile |
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
KR20080076667A (ko) * | 2007-02-15 | 2008-08-20 | 주식회사 중외제약 | 요변성 약학 조성물 |
CA2773249A1 (en) * | 2009-09-10 | 2011-03-17 | Bial-Portela & C.A., S.A. | Oral suspension formulations of esclicarbazepine acetate |
CN104288104A (zh) * | 2014-09-24 | 2015-01-21 | 万特制药(海南)有限公司 | 奥卡西平干混悬剂及其制备方法 |
EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
CN109010322A (zh) * | 2018-07-13 | 2018-12-18 | 山东达因海洋生物制药股份有限公司 | 一种包含奥卡西平的口腔分散膜剂及其制备方法 |
CN115487145B (zh) * | 2022-10-10 | 2023-09-01 | 上海奥科达医药科技股份有限公司 | 一种奥卡西平口服混悬液及其制备方法 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH500196A (de) | 1969-03-10 | 1970-12-15 | Ciba Geigy Ag | Verfahren zur Herstellung von neuen Azepinderivaten |
US4004029A (en) * | 1974-05-13 | 1977-01-18 | The Upjohn Company | Compositions and method for treating epilepsy and convulsions |
US4431641A (en) * | 1980-10-17 | 1984-02-14 | Ciba-Geigy Corporation | Pharmaceutical compositions having antiepileptic and antineuralgic action |
RO81639A2 (ro) * | 1981-02-27 | 1983-06-01 | Intreprinderea De Medicamente "Biofarm",Ro | Procedeu de obtinere a unei pulberi suspendabile oxrale de ampicilina |
CH649080A5 (de) | 1981-04-16 | 1985-04-30 | Ciba Geigy Ag | 5h-dibenz(b,f)azepin-5-carboxamide als mittel zur prophylaxe und behandlung von zerebraler leistungsinsuffizienz. |
US4427681A (en) | 1982-09-16 | 1984-01-24 | Richardson-Vicks, Inc. | Thixotropic compositions easily convertible to pourable liquids |
JPS60204713A (ja) | 1984-03-30 | 1985-10-16 | Zenyaku Kogyo Kk | 水性懸濁組成物 |
US4693901A (en) | 1985-12-10 | 1987-09-15 | Cardinal Biological, Ltd. | Shelf stable dairylike products |
GB8618847D0 (en) | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
IL90245A (en) | 1988-05-11 | 1994-04-12 | Glaxo Group Ltd | Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it |
EP0373103B1 (de) | 1988-11-10 | 1993-03-31 | Ciba-Geigy Ag | Flüssige orale Formulierung |
GB9102579D0 (en) | 1991-01-24 | 1991-03-27 | Glaxo Group Ltd | Compositions |
US5272137A (en) | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
GB9219524D0 (en) * | 1992-09-15 | 1992-10-28 | Smithkline Beecham Plc | Novel composition |
FR2699077B1 (fr) | 1992-12-16 | 1995-01-13 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes. |
JP3254219B2 (ja) * | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のci−981製剤およびその製法 |
FR2702148B1 (fr) | 1993-03-05 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
FR2702151B1 (fr) | 1993-06-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application d'anticonvulsivants dans le traitement du neuro-sida. |
FR2702149B1 (fr) | 1993-06-03 | 1995-04-07 | Rhone Poulenc Rorer Sa | Application de la lamotrigine dans le traitement du neuro-sida. |
US5472714A (en) * | 1993-09-08 | 1995-12-05 | Ciba-Geigy Corporation | Double-layered oxcarbazepine tablets |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
NZ295132A (en) | 1994-10-14 | 1998-06-26 | Janssen Pharmaceutica Nv | Sabeluzole aqueous suspension having ph from 8 to 10 |
DE4443966A1 (de) * | 1994-12-09 | 1996-06-13 | Basf Ag | Thermoplastische Formmassen |
PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
IT1277663B1 (it) | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | Sospensioni acquose stabili di mesalazina per uso topico |
PT101876B (pt) * | 1996-05-27 | 1999-09-30 | Portela & Ca Sa | Novos derivados de 10,11-di-hidro-10-oxo-5h-dibenzo(b,f)azepina-5-carboxamida |
IT1286496B1 (it) | 1996-11-20 | 1998-07-15 | Leetrim Ltd Dublin | Composizione farmaceutica orale ad attivita' antipiretica,analgesica ed antiinfiammatoria |
US6037380A (en) * | 1997-04-11 | 2000-03-14 | Fmc Corporation | Ultra-fine microcrystalline cellulose compositions and process |
US6146876A (en) * | 1999-06-11 | 2000-11-14 | Millennium Pharmaceuticals, Inc. | 22025, a novel human cyclic nucleotide phosphodiesterase |
GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
-
1999
- 1999-12-20 GB GBGB9930058.4A patent/GB9930058D0/en not_active Ceased
-
2000
- 2000-12-12 CO CO00094330A patent/CO5261608A1/es not_active Application Discontinuation
- 2000-12-13 FR FR0016220A patent/FR2802423B1/fr not_active Expired - Lifetime
- 2000-12-14 BE BE2000/0787A patent/BE1013706A5/fr not_active IP Right Cessation
- 2000-12-15 IT IT2000MI002717A patent/ITMI20002717A1/it unknown
- 2000-12-18 AR ARP000106730A patent/AR030175A1/es not_active Application Discontinuation
- 2000-12-18 PE PE2000001359A patent/PE20010933A1/es not_active Application Discontinuation
- 2000-12-19 RU RU2002119210/15A patent/RU2277912C2/ru active
- 2000-12-19 KR KR10-2004-7015495A patent/KR20040098034A/ko not_active Application Discontinuation
- 2000-12-19 KR KR10-2002-7007846A patent/KR100496368B1/ko active IP Right Grant
- 2000-12-19 DK DK00988803T patent/DK1239832T3/da active
- 2000-12-19 AT AT00988803T patent/ATE269694T1/de active
- 2000-12-19 CN CN008173478A patent/CN1216594C/zh not_active Expired - Lifetime
- 2000-12-19 TR TR2002/01459T patent/TR200201459T2/xx unknown
- 2000-12-19 WO PCT/EP2000/012968 patent/WO2001045671A2/en active Application Filing
- 2000-12-19 EP EP20040007509 patent/EP1437127A1/en not_active Withdrawn
- 2000-12-19 HU HU0203782A patent/HU226486B1/hu unknown
- 2000-12-19 IL IL14949800A patent/IL149498A0/xx unknown
- 2000-12-19 EP EP00988803A patent/EP1239832B1/en not_active Expired - Lifetime
- 2000-12-19 CA CA2390029A patent/CA2390029C/en not_active Expired - Lifetime
- 2000-12-19 PT PT00988803T patent/PT1239832E/pt unknown
- 2000-12-19 SK SK865-2002A patent/SK287553B6/sk not_active IP Right Cessation
- 2000-12-19 MY MYPI20005952A patent/MY126868A/en unknown
- 2000-12-19 ES ES00988803T patent/ES2223641T3/es not_active Expired - Lifetime
- 2000-12-19 MX MXPA02006142A patent/MXPA02006142A/es active IP Right Grant
- 2000-12-19 AU AU25118/01A patent/AU777619B2/en not_active Expired
- 2000-12-19 DE DE60011809T patent/DE60011809T2/de not_active Expired - Lifetime
- 2000-12-19 PL PL355535A patent/PL201331B1/pl unknown
- 2000-12-19 TR TR2004/02419T patent/TR200402419T4/xx unknown
- 2000-12-19 NZ NZ518755A patent/NZ518755A/en not_active IP Right Cessation
- 2000-12-19 BR BR0016524-7A patent/BR0016524A/pt not_active Application Discontinuation
- 2000-12-19 US US10/168,248 patent/US8119148B2/en not_active Expired - Fee Related
- 2000-12-19 CZ CZ20022138A patent/CZ302737B6/cs not_active IP Right Cessation
- 2000-12-19 JP JP2001546410A patent/JP4588281B2/ja not_active Expired - Lifetime
-
2001
- 2001-11-30 BE BE2001/0779A patent/BE1014502A5/fr not_active IP Right Cessation
-
2002
- 2002-05-06 IL IL149498A patent/IL149498A/en active IP Right Grant
- 2002-06-14 NO NO20022849A patent/NO331990B1/no not_active IP Right Cessation
- 2002-06-28 ZA ZA200204863A patent/ZA200204863B/xx unknown
-
2003
- 2003-02-14 HK HK03101098A patent/HK1050474A1/xx unknown
-
2006
- 2006-08-14 JP JP2006221159A patent/JP2006312651A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5261608A1 (es) | Composicion farmaceutica en forma de una suspension que comprende oxcarbazepina | |
MXPA03000190A (es) | Composicion para el suministro del factor de crecimiento hamtopoyetico. | |
BR0211736A (pt) | Formulação para suspensão oral estabilizada | |
MXPA05008909A (es) | Formulacion intranasal de rotigotina. | |
MXPA02011543A (es) | Preparacion de suspensiones inyectables las cuales tienen capacidad de inyeccion mejorada. | |
PL366314A1 (en) | Pharmaceutical compositions | |
WO2007130906A3 (en) | Malleable implants containing demineralized bone matrix | |
ES2570856T3 (es) | Composiciones oftálmicas que contienen una combinación sinérgica de dos polímeros | |
BR9810658A (pt) | Composições farmacêuticas contendo hemissulfato de eletriptano e cafeìna. | |
TW200621745A (en) | Novel benzo-fused heteroaryl sulfamide derivatives useful as anticonvulsant agents | |
AR067077A1 (es) | Preparado solido farmaceutico y metodo de produccion del mismo | |
TW200501965A (en) | Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle | |
ES2720954T3 (es) | Formulaciones estabilizadas de estatina | |
RU2012113844A (ru) | Пероральные суспензионные лекарственные формы ацетата эсликарбазепина | |
MY135548A (en) | Aqueous preparation containing oligopeptides and etherified cyclodextrin | |
TW200624119A (en) | An oral liquid pharmaceutical composition of leukotriene antagonists | |
UY27229A1 (es) | Composición | |
BR0007473A (pt) | Composições tendo estabilidade melhorada | |
WO2004022699A3 (en) | Liquid stable composition of oxazaphosphorine with mesna | |
TW200502235A (en) | Novel benzo[1,2,5]thiadiazoles and pharmaceutical use thereof | |
ATE211002T1 (de) | Dextrinhaltige mischung zur verhinderung von chirurgischen verklebungen | |
PL366513A1 (en) | Thickened aqueous compositions | |
TW200509990A (en) | Pharmaceutical formulations | |
MXPA05013433A (es) | Formulaciones farmaceuticas que comprenden amoxicilina y clavulanato. | |
TNSN07288A1 (en) | Composition containing chitosan for sustained drug release |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |